Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Camptothecin
/ adverse effects
Colonic Neoplasms
/ drug therapy
Colorectal Neoplasms
/ drug therapy
Fluorouracil
Genes, ras
Humans
Irinotecan
/ therapeutic use
Leucovorin
Organoplatinum Compounds
Oxaliplatin
Panitumumab
Prospective Studies
Proto-Oncogene Proteins B-raf
/ genetics
Rectal Neoplasms
/ drug therapy
ras Proteins
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
pubmed:
7
6
2022
medline:
1
9
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
To verify whether the intensification of the upfront chemotherapy backbone with a modified schedule of modified fluorouracil, leucovorin, oxaliplatin, and irinotecan (mFOLFOXIRI) increases the activity of fluorouracil, leucovorin, and oxaliplatin when both regimens are combined with panitumumab as initial treatment for TRIPLETE was a prospective, open-label, phase III trial in which previously untreated patients with unresectable From September 2017 to September 2021, 435 patients were enrolled (control group/experimental group: 217/218) in 57 Italian sites. One hundred sixty (73%) patients treated with mFOLFOXIRI plus panitumumab and 165 (76%) patients treated with modified FOLFOX plus panitumumab achieved RECIST response (odds ratio 0.87, 95% CI, 0.56 to 1.34, The intensification of the upfront chemotherapy backbone in combination with panitumumab does not provide additional benefit in terms of treatment activity at the price of increased gastrointestinal toxicity in patients with
Identifiants
pubmed: 35666229
doi: 10.1200/JCO.22.00839
pmc: PMC9426812
doi:
Substances chimiques
Organoplatinum Compounds
0
Oxaliplatin
04ZR38536J
Panitumumab
6A901E312A
Irinotecan
7673326042
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
ras Proteins
EC 3.6.5.2
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Camptothecin
XT3Z54Z28A
Banques de données
ClinicalTrials.gov
['NCT03231722']
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2878-2888Références
Eur J Cancer. 2017 Jan;70:87-98
pubmed: 27907852
Lancet Oncol. 2016 Oct;17(10):1426-1434
pubmed: 27575024
Oncologist. 2011;16(11):1557-64
pubmed: 22016477
Ann Oncol. 2018 Jan 1;29(1):44-70
pubmed: 29155929
J Natl Cancer Inst. 2015 Feb 24;107(3):
pubmed: 25713148
Int J Colorectal Dis. 2017 Aug;32(8):1179-1190
pubmed: 28424871
JAMA Oncol. 2018 Apr 01;4(4):529-536
pubmed: 29450468
Br J Cancer. 2010 Nov 9;103(10):1542-7
pubmed: 20959822
Clin Colorectal Cancer. 2015 Jun;14(2):81-90
pubmed: 25666296
Br J Cancer. 2022 May;126(9):1264-1270
pubmed: 34992255
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Oncol. 2017 Aug 01;28(8):1713-1729
pubmed: 28407110
Ann Oncol. 2013 Aug;24(8):2062-7
pubmed: 23666916
Lancet Oncol. 2014 Sep;15(10):1065-75
pubmed: 25088940
J Clin Oncol. 2015 Mar 1;33(7):692-700
pubmed: 25605843
Eur J Cancer. 2015 Sep;51(14):1927-36
pubmed: 26188850
J Clin Oncol. 2019 Nov 20;37(33):3099-3110
pubmed: 31539295
Eur J Cancer. 2015 Mar;51(5):587-94
pubmed: 25673558
J Clin Oncol. 2020 Aug 20;:JCO2001225
pubmed: 32816630
Ann Oncol. 2017 Dec 01;28(12):3009-3014
pubmed: 29045518
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
J Clin Oncol. 2014 Jul 20;32(21):2240-7
pubmed: 24687833
J Clin Oncol. 2019 Dec 10;37(35):3401-3411
pubmed: 31609637
Br J Cancer. 2015 Jun 9;112(12):1888-94
pubmed: 25989278
N Engl J Med. 2013 Sep 12;369(11):1023-34
pubmed: 24024839